{"contentid": 488510, "importid": NaN, "name": "Vertex reports strong 1st-qtr sales growth", "introduction": "US biopharma company Vertex Pharmaceuticals has reported consolidated financial results for the first quarter of 2021 and reiterated full-year 2021 guidance for product revenues.", "content": "<p>US biopharma company Vertex Pharmaceuticals (Nasdaq: VRTX) has reported consolidated financial results for the first quarter of 2021 and reiterated full-year 2021 guidance for product revenues.</p>\n<p>Product revenues increased 14% to $1.72 billion compared to the first quarter of 2020, topping the average analysts' revenue estimate of $1.66 billion, primarily driven by the uptake of cystic fibrosis (CF) treatments Kaftrio/Trikafta (ivacaftor/tezacaftor/elexacaftor) in Europe and continued performance of Trikafta in the USA. Net product revenues in the first quarter of 2021 increased 6% to $1.25 billion in the USA and increased 43% to $470 million outside the USA, compared to the prior year.</p>\n<p>Vertex announced net income of $653 million, or $2.49 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, its GAAP earnings totaled $603 million, or $2.29 per share. Adjusted net income of $781 million, or $2.98 per share, well ahead of Wall street&rsquo;s estimate of $2.69 per share.</p>\n<p>\"In CF, our goal is that all eligible patients have access to and can benefit from CFTR modulators. In the first quarter, we continued to make significant progress towards this goal, and in so doing again delivered strong revenue and earnings growth,&rdquo; said Dr Reshma Kewalramani, chief executive and president of Vertex.</p>\n<h2><strong>Pipeline progress</strong></h2>\n<p>He continued: \"Beyond CF, we have also seen continued significant progress across our broad pipeline, including advancement of VX-548 to Phase II in acute pain, initiation of the Phase I/II clinical trial with VX-880 in type 1 diabetes and completion of enrollment and dosing in our Phase II proof-of-concept study with the AAT corrector, VX-864. The recent amendment of our agreement with CRISPR Therapeutics for the CTX001 program further enhances our leadership position in cell and genetic therapies and we look forward to completing enrollment of our ongoing trials for CTX001 in sickle cell disease and beta thalassemia this year and bringing this first-in-class treatment to patients with these devastating diseases as soon as possible.&rdquo;</p>\n<h2><strong>Product performances</strong></h2>\n<p>Sales of Vertex&rsquo; newest CF drug Trikafta/Kaftrio, which treats 90% of patients with the lung disease, surged 123% to $1.19 billion.</p>\n<p>Orkambi (lumacaftor/ivacaftor) revenues fell 6.4% to $219 million.</p>\n<p>Kalydeco (ivacaftor) sales fell 12.7% to $186 million.</p>\n<p>Symedco/Symkevi (tezacaftor/ivacaftor) sales of $125 million were down 28%.</p>", "date": "2021-04-30 14:39:00", "meta_title": "Vertex reports strong 1st-qtr sales growth", "meta_keywords": "Vertex Pharmaceuticals, Financial results, First-quarter, 2021. Cystic fibrosis, Kalydeco, Kaftrio, Orkambi, Symdeco, Symkevi, Trikafta", "meta_description": "Vertex reports strong 1st-qtr sales growth", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-30 14:36:40", "updated": "2021-04-30 14:48:36", "access": NaN, "url": "https://www.thepharmaletter.com/article/vertex-reports-strong-1st-qtr-sales-growth", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "vertex-big.jpg", "image2id": "vertex-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Rare diseases, Respiratory and Pulmonary", "topic_tag": "Financial, Management, Research", "geography_tag": "USA", "company_tag": "Vertex Pharmaceuticals", "drug_tag": "Kaftrio, Kalydeco, Orkambi, Symdeko, Symkevi, Trikafta", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-30 14:39:00"}